Tirzepatide
Molecular Formula: C225H348N48O68
Molecular Weight: ~4813.5 g/mol
Structure: Dual incretin mimetic peptide (GLP-1 and GIP receptor agonist) with fatty acid modification for extended half-life
Form: Lyophilized peptide, ≥98% purity
Synonyms: LY3298176, Dual GLP-1/GIP agonist
Overview
Tirzepatide is a synthetic dual incretin mimetic peptide designed to activate both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. By combining the effects of two incretin pathways, Tirzepatide represents a novel class of investigational peptides studied for metabolic health, obesity, and glucose regulation.
Its structural modifications, including a fatty acid chain, extend its half-life through albumin binding, enabling sustained receptor activation and making it a powerful candidate in metabolic research.
Mechanism of Action
Research indicates that Tirzepatide functions by:
GLP-1 Receptor Agonism: Enhances glucose-dependent insulin secretion and reduces glucagon release.
GIP Receptor Agonism: Improves insulin sensitivity and potentiates the effects of GLP-1 activity.
Appetite Regulation: Modulates central pathways that reduce hunger and caloric intake in experimental models.
Gastric Emptying: Slows nutrient absorption, contributing to post-prandial glucose control.
Extended Activity: Albumin binding increases circulating half-life, supporting once-weekly dosing in research settings.
Research Areas
Tirzepatide is being investigated in preclinical and translational studies for:
Type 2 Diabetes Research: Assessing dual incretin action on glycemic control.
Obesity & Weight Loss Models: Exploring appetite regulation and fat mass reduction.
Cardiometabolic Health: Studying effects on cholesterol, triglycerides, and inflammatory markers.
Insulin Sensitivity: Evaluating improvements in glucose uptake and utilization.
Neuroendocrine Research: Investigating metabolic effects on brain–gut signaling pathways.
Handling & Storage
Storage (lyophilized): –20°C in a dry, light-protected environment.
Reconstitution: Reconstitute with sterile water or buffer.
Stability: Store reconstituted solution at 2–8°C; avoid repeated freeze–thaw cycles.
Disclaimer
Tirzepatide is intended solely for laboratory and preclinical research purposes.
It is not approved for human or veterinary use and must not be used for diagnosis, treatment, or self-administration. Applications are restricted to controlled research environments only.
